SH3PXD2B (SH3 And PX Domains 2B)

To our knowledge, the SH3PXD2B::FER fusion has never been reported previously. Whether the current case represents an example of a plexiform myofibroblastic tumor or a distinct tumor entity remains to be determined.

High TTP expression is considered as a positive prognostic marker in multiple cancers, including BC. Given that doxorubicin is a commonly used drug for treating triple-negative BC, using TTP as a prognostic marker in this cohort of patients might be limited since it might be challenging to understand if high TTP expression occurred due to the favorable physiological state of the patient or as a consequence of treatment.

Our on-going experiments aim to validate experimentally the in silico data using a cohort of 80 glioma patients, including paired primary and recurrent tumor tissues. Conclusions The identification of a prognostic/predictive miRNA signature and its target genes, with a potential key role in glioma progression/recurrence through the regulation of important biological processes, could represent a step forward for the development of novel complementary therapies useful for patients management.

Our study strongly suggests that SH3PXD2B is a carcinogenic molecule that can be used as a biomarker for GC detection, prognosis, treatment design, and follow-up.

Based on these findings, we can develop more and more effective treatments for cervical cancer patients. Based on the gene enriched pathways, we can development specific drugs targeting the pathways.